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Summary
Background: Although the metabolic syndrome is associated with incident cardiovas-
cular disease, low-density lipoprotein (LDL) cholesterol is a well-known risk factor
for coronary atherosclerosis. The aim of this study was to clarify the clinical markers
for coronary plaque vulnerability in acute coronary syndrome (ACS) patients (men)
without the metabolic syndrome.
Methods: Consecutive Japanese men with ACS (n = 264) underwent emergent
coronary angiography and B-mode carotid ultrasonography. Common carotid intima-
media thickening and vascular dilatation were considered to indicate carotid artery
remodeling. Patients were divided into two groups based on the number of complex
plaques identiﬁed by coronary angiography.
Results: Abdominal obesity and low high-density lipoprotein cholesterol levels were
frequently observed in overall patients with multiple complex coronary lesions.
Although the metabolic syndrome was a signiﬁcant independent predictor of mul-
tiple complex coronary lesions in overall ACS patients, a high LDL cholesterol level
was an independent predictor in ACS patients without the metabolic syndrome.
Carotid artery remodeling was an independent predictor of multiple complex coro-
nary lesions in both overall patients and patients without the metabolic syndrome.
Conclusion: In ACS patients ithout the metabolic syndrome, high LDL cholesterol
levels and carotid artery re
cacy of aggressive treatmen
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modeling are important indicators for assessing the efﬁ-
ts for secondary prevention of ACS.
Cardiology. Published by Elsevier Ireland Ltd. All rights
.
gy. Published by Elsevier Ireland Ltd. All rights reserved.
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Cyslipidemia in ACS men without metabolic syndrom
ntroduction
he metabolic syndrome is deﬁned as the clus-
ering of cardiovascular disease risk factors in
n individual, including impaired glucose toler-
nce, hypertension, dyslipidemia, and abdominal
besity [1—3]. Components of the metabolic syn-
rome are common and are associated with
ncident cardiovascular disease and diabetes [4,5].
n contrast, the presence of multiple complex
oronary lesions identiﬁed with coronary angiog-
aphy has been reported to be associated with
n increased incidence of recurrent acute coro-
ary syndrome (ACS) [6,7]. Goldstein et al. [8]
eported that the presence of multiple complex
laques was a strong predictor of adverse car-
iovascular events at 1 year. Our previous study
9] showed that the metabolic syndrome is a
seful independent predictor of multiple com-
lex coronary lesions in Japanese men with ACS.
e demonstrated that abdominal obesity and low
evels of high-density lipoprotein (HDL) choles-
erol, but not high levels of low-density lipoprotein
LDL) cholesterol, seemed to be the key factors
n predicting a greater risk of complex coronary
esions.
It is well established that a low level of HDL
holesterol is a strong predictor of increased car-
iovascular disease risk [10—12]. According to
he subanalysis of Myocardial Ischemia Reduc-
ion with Aggressive Cholesterol Lowering (MIRACL)
tudy [13], plasma HDL cholesterol, but not LDL
holesterol, measured in the initial stage of
CS predicts the risk of recurrent cardiovascu-
ar events. However, another study demonstrated
progressive reduction in the beneﬁt of inten-
ive lipid-lowering therapy with statins in ACS
atients, as the baseline LDL cholesterol decreased
14].
Carotid intima-media thickness (IMT) measured
y high-resolution B-mode ultrasonography has
een proposed as a clinically useful marker for the
evelopment of atherosclerosis and its response to
herapy [15,16]. Previously, we showed that multi-
le complex coronary plaques in ACS are associated
ith carotid remodeling [17].
Although the metabolic syndrome is an impor-
ant predictor of risk stratiﬁcation of recurrent
cute coronary events in men with ACS [9], LDL
holesterol is a well-known risk factor for coronary
therosclerosis [18]. Important markers for ACS in
atients without the metabolic syndrome remain
nclear. The aim of this study was to identify the
linical markers for coronary plaque vulnerability
n Japanese men with ACS without the metabolic
yndrome.
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ethods
tudy population
his study included 264 consecutive male patients
ith ACS who were admitted to the Coronary Care
nit of Hiroshima City Asa Hospital. The patients
ad ischemic chest discomfort with ST-segment
levation or depression of >0.5mm or T-wave inver-
ion in two or more leads. Among these patients,
34 had acute myocardial infarction diagnosed on
he basis of elevated serum levels of creatine
inase (more than twice the upper limit for healthy
umans) and creatine kinase-MB fraction (>10% of
he total creatine kinase). Thirty patients did not
how elevated levels of creatine kinase-MB frac-
ion, and these patients were classiﬁed as having
nstable angina. All the patients underwent angiog-
aphy to document the responsible coronary lesions
ithin 24 h after the onset of chest pain. Patients
ith a history of myocardial infarction, coronary
rtery bypass grafting, or carotid surgery were
xcluded. Informed consent was obtained from all
atients after providing an explanation of the study.
Patients were divided into two groups based
n the number of complex plaques identiﬁed
y coronary angiography. Metabolic abnormalities
ere determined using the Japanese criteria for
he metabolic syndrome [19]. Patients with the
etabolic syndrome had to satisfy the following
riteria: abdominal obesity (waist circumference
85 cm) as an essential factor combined with 2
r more of the following factors: fasting triglyc-
ride level ≥150mg/dl and/or HDL cholesterol
evel <40mg/dl; high blood pressure (systolic
lood pressure ≥130mmHg, diastolic blood pres-
ure ≥85mmHg) or use of antihypertensive drug
herapy; or fasting glucose level ≥110mg/dl. Blood
amples were analyzed at a hemodynamically
teady state 1 week after the onset of ACS.
Diabetes was deﬁned as the presence of any
f the following factors: fasting serum glucose
evel ≥126mg/dl, fasting glucose level ≥200mg/dl,
elf-reported use of medications for diabetes,
nd self-reported previous physician’s diagnosis.
DL cholesterol levels were calculated with the
riedewald formula [20]. High LDL cholesterolemia
as deﬁned as a serum LDL cholesterol level of
140mg/dl.
oronary angiographyoronary angiography was performed with the
tandard Judkins technique and the results were
nalyzed as previously described, with substantial
esions (which narrowed the vessel diameter by
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>50%) being measured quantitatively [21]. Com-
plex coronary plaques were identiﬁed according
to the following criteria [6,22,23]: an intraluminal
ﬁlling defect consistent with a thrombus, deﬁned
as an abrupt vessel obstruction with persistence
of contrast or an intraluminal ﬁlling defect in a
patent vessel within or adjacent to a stenotic
region with surrounding homogeneous opaciﬁcation
by contrast; plaque ulceration, deﬁned as the pres-
ence of contrast and a hazy contour beyond the
vessel lumen; plaque irregularity, deﬁned as irreg-
ular margins or overhanging edges; and impaired
ﬂow. Lesions were considered complex if there was
>50% luminal narrowing and they showed two or
more of the above mentioned morphologic fea-
tures, whereas lesions characteristic of chronic
total occlusion or >50% luminal narrowing without
or with one of these morphologic features was con-
sidered simple.
The location of the responsible lesion was deter-
mined by correlating the presence of a complex
lesion with electrocardiographic and wall motion
abnormalities. In each patient, the coronary vas-
culature was reviewed to identify anatomically
remote complex lesions. An anatomically remote
lesion was deﬁned as a lesion in an artery differ-
ent from that containing the responsible lesion, in
a different branch of the same artery or in the
same branch, but at least 5 cm from the responsible
lesion with an intervening disease-free segment.
The angiograms were analyzed by two independent
angiographers (K.D. and S.S.). The results were
compared and a ﬁnal decision was made by con-
sensus in case of a disagreement.
Ultrasound evaluation
High-resolution B-mode ultrasonography was per-
formed within 1 week of coronary angiography in
all patients by a single trained sonographer using
an 11.3-MHz linear array ultrasound imaging system
(SONOS 5500, Philips Medical Systems, Andover, MA,
USA or SSD-2000, Aloka Co. Ltd., Tokyo, Japan). The
left and right carotid arteries were scanned with
the beam focused on the near and far walls of the
distal 2 cm of the common carotid artery proximal
to its bifurcation. Both longitudinal and transverse
images were obtained to study the plaques. When
an optimal longitudinal image was obtained, it was
frozen in end-diastole.
The carotid IMT was measured as the distance
from the leading edge of the ﬁrst echogenic line
to that of the second echogenic line. The ﬁrst line
represented the luminal—intimal interface, and the
second line represented the collagen-containing
upper layer of the tunica adventitia. The distance
C
m
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rom the ﬁrst line of the near wall to that of the far
all was deﬁned as the luminal diameter, and the
istance from the second line of the near wall to
hat of the far wall was deﬁned as the interadven-
itial diameter. Using longitudinal images, the max-
mum and minimum IMT values of the far wall, their
verage, and the maximum luminal and interadven-
itial diameters were determined by the same oper-
tor (M.K.), who was blinded to the results of coro-
ary angiography. All measurements were made
sing electronic calipers. Hyperechoic segments
f the carotid wall were identiﬁed as calciﬁed
therosclerotic segments. On the basis of our previ-
us study, carotid artery remodeling was deﬁned by
he morphology of the common carotid artery, i.e.,
mean value of maximum andminimum carotid IMT
1.1mm and an interadventitial diameter >8.0mm
17]. Carotid plaques were deﬁned as a distinct area
ith an IMT 50% thicker than the neighboring sites
y visual assessment. Calciﬁcation was indicated as
ny hyperechoic region.
tatistical analysis
he results are presented as the mean± S.D.
nivariate analysis was performed using Student’s
test. Categorical data were compared against a
hi-squared distribution. The optimal cut-off values
or the ratio of LDL to HDL cholesterol for multiple
omplex coronary lesions were determined from
eceiver—operator characteristic (ROC) curve anal-
sis. Clinical and carotid ultrasonographic variables
ere entered into a multivariate logistic regression
odel of multiple complex coronary lesions to test
or their independent effects. Independent clinical
ariables included older age (>65 years), myocar-
ial infarction, hypertension, diabetes mellitus,
igh LDL cholesterol level (>140mg/dl), current
moking, ischemia family history (only including
oronary artery disease), and the metabolic syn-
rome. Carotid ultrasonographic variables included
arotid plaque, carotid calciﬁcation, and carotid
rtery remodeling. Odds ratios and 95% conﬁdence
ntervals were calculated to assess the predic-
ive value. P < 0.05 was considered statistically
igniﬁcant.
esultslinical characteristics and carotid artery
orphology in overall ACS patients
he clinical characteristics of patients with single
nd multiple complex coronary lesions are shown
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Table 1 Clinical characteristics of acute coronary syndrome patients with single and multiple complex coronary
lesions.
Complex coronary lesion
Single (n = 167) Multiple (n = 97) P-value
Age (years) 64.0± 10.5 64.1± 10.3 0.96
Acute myocardial infarction 146 (87%) 88 (91%) 0.42
Body mass index (kg/m2) 23.0± 3.1 24.1± 3.2 <0.007
Waist circumference (cm) 82.7± 7.9 85.9± 8.2 <0.003
Metabolic syndrome 47 (28%) 44 (45%) <0.005
Abdominal obesity 70 (42%) 54 (56%) <0.04
Low HDL cholesterolemia 64 (38%) 50 (52%) <0.04
High blood pressure 112 (67%) 74 (76%) 0.11
Hypertriglyceridemia 46 (28%) 33 (34%) 0.27
Hyperglucosemia 64 (38%) 47(48%) 0.11
Hypertension 100 (60%) 73 (75%) <0.02
Diabetes mellitus 54 (32%) 41 (42%) 0.11
High LDL cholesterolemia 47 (28%) 32 (33%) 0.41
Current smoking 93 (56%) 49 (51%) 0.42
Ischemic family history 17 (10%) 7 (7%) 0.41
Total cholesterol (mg/dl) 194± 30 198± 41 0.41
HDL cholesterol (mg/dl) 44± 11 41± 10 0.008
LDL cholesterol (mg/dl) 124± 28 129± 38 0.16
LDL cholesterol/HDL cholesterol ratio 2.97± 0.99 3.34± 1.09 0.005
Fasting triglycerides (mg/dl) 129± 63 137± 59 0.31
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Values are mean± S.D. or number (%). High blood pressure is d
is deﬁned as a serum LDL cholesterol level >140mg/dl. HDL, h
n Table 1. Levels of LDL cholesterol were similar
etween the two groups. The metabolic syndrome
as identiﬁed in 91 patients (34%). As in our pre-
ious study, abdominal obesity and low levels of
DL cholesterol were the characteristics of the
etabolic syndrome that were most frequently
bserved in patients with multiple complex coro-
ary lesions.
B-mode ultrasonographic features of the com-
on carotid artery are shown in Table 2. The carotid
MT was signiﬁcantly greater in ACS patients with
ultiple complex coronary lesions than in patients
ith solitary lesions. Furthermore, patients with
ultiple complex lesions had a signiﬁcantly greater
arotid interadventitial diameter and the ratio of
nteradventitial diameter to luminal diameter than
id those with solitary complex lesions. The fre-
uency of carotid plaques was also higher in the
roup with multiple complex lesions.
linical characteristics and carotid artery
orphology in ACS patients without the
etabolic syndrome
he clinical characteristics of patients without the
etabolic syndrome are shown in Table 3. Although
P
i
d
3
m114± 30 0.16
d as blood pressure ≥130/85mmHg. High LDL cholesterolemia
ensity lipoprotein; LDL, low-density lipoprotein.
he prevalence of abdominal obesity and low lev-
ls of HDL cholesterol was signiﬁcantly higher in
verall patients with multiple complex coronary
esions, it was similar between the two groups in
atients without the metabolic syndrome. In con-
rast, in patients without the metabolic syndrome,
he levels of LDL cholesterol were signiﬁcantly
igher in the group with multiple complex coronary
esions.
The carotid IMT and the ratio of interadventi-
ial diameter to luminal diameter were signiﬁcantly
reater in patients with multiple complex coro-
ary lesions than in those with solitary lesions
Table 4). The frequency of carotid plaques was also
igher in the group with multiple complex coronary
esions.
ptimal ratios of LDL to HDL cholesterol for
redicting multiple complex coronary
esionsatients with multiple complex lesions had a signif-
cantly greater ratio of LDL to HDL cholesterol than
id those with solitary complex lesions (Tables 1 and
). The ROC curve analysis indicated that the opti-
al ratio of LDL to HDL cholesterol for predicting
398 M. Kato et al.
Table 2 Carotid ultrasonographic ﬁndings in acute coronary syndrome patients with single and multiple complex
coronary lesions.
Complex coronary lesion
Single (n = 167) Multiple (n = 97) P-value
IMTmean (mm) 0.87± 0.17 1.02± 0.20 <0.0001
IMTmin (mm) 0.78± 0.15 0.91± 0.18 <0.0001
IMTmax (mm) 0.96± 0.20 1.13± 0.23 <0.0001
IMTmean > 1.1mm 14 (8%) 36 (37%) <0.0001
IAD (mm) 7.73± 0.99 8.18± 1.03 0.0005
IAD > 8.0mm 48 (29%) 50 (52%) 0.0002
LD (mm) 6.17± 0.85 6.35± 0.90 0.11
LD/IAD ratio 1.26± 0.06 1.29± 0.08 <0.0001
Carotid remodeling 9 (5%) 28 (29%) <0.0001
Plaque 46 (28%) 43 (44%) <0.006
Calciﬁcation 35 (21%) 29 (30%) 0.10
mete
ess; L
I
c
T
eValues are mean± S.D. or number (%). IAD, interadventitial dia
intima-media thickness; IMTmin, minimal intima-media thickn
the presence of multiple complex coronary lesions
was 3.18, with a sensitivity of 61% and a speci-
ﬁcity of 59% (area under curve: 0.60; P < 0.006) in
overall patients with ACS. In patients without the
metabolic syndrome, the optimal ratio of LDL to
HDL cholesterol for predicting the presence of mul-
tiple complex coronary lesions was also 3.18 with
a sensitivity of 55% and a speciﬁcity of 68% (area
under curve: 0.63; P < 0.003).
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Table 3 Clinical characteristics of acute coronary syndrom
Complex
Single (n
Age (years) 64.8± 1
Acute myocardial infarction 103 (86%)
Body mass index (kg/m2) 22.1± 2
Waist circumference (cm) 79.7± 6
Abdominal obesity 23 (19%)
Low HDL cholesterolemia 36 (30%)
High blood pressure 68 (57%)
Hypertriglyceridemia 25 (21%)
Hyperglucosemia 40 (33%)
Hypertension 64 (53%)
Diabetes mellitus 34 (28%)
High LDL cholesterolemia 29 (24%)
Current smoking 70 (58%)
Ischemic family history 8 (7%)
Total cholesterol (mg/dl) 192± 30
HDL cholesterol (mg/dl) 46± 11
LDL cholesterol (mg/dl) 121± 29
LDL cholesterol/HDL cholesterol ratio 2.77±
Fasting triglycerides (mg/dl) 120± 61
Fasting glucose (mg/dl) 103± 30
Values are mean± S.D. or number (%). High blood pressure is deﬁne
is deﬁned as a serum LDL cholesterol level >140mg/dl. HDL, high-dr; IMTmax, maximal intima-media thickness; IMTmean, mean
D, luminal diameter.
ndependent predictors of multiple complex
oronary lesions
he signiﬁcant independent predictors of the pres-
nce of multiple complex coronary lesions in overall
CS patients were the metabolic syndrome and
arotid artery remodeling (Table 5). In ACS patients
ithout the metabolic syndrome, the signiﬁcant
ndependent predictors of multiple complex coro-
e patients without metabolic syndrome.
coronary lesion
= 120) Multiple (n = 53) P-value
0.7 63.3± 10.2 0.41
50 (94%) 0.11
.3 22.4± 2.3 0.32
.9 80.5± 5.7 0.46
10 (19%) 0.96
21 (40%) 0.21
36 (68%) 0.16
12 (23%) 0.79
22 (42%) 0.30
36 (68%) 0.07
19 (36%) 0.32
22 (42%) <0.03
30 (57%) 0.83
4 (8%) 0.83
204± 48 <0.05
43± 11 0.08
136± 46 <0.02
0.10 3.33± 1.25 <0.002
124± 38 0.67
111± 29 0.13
d as blood pressure ≥130/85mmHg. High LDL cholesterolemia
ensity lipoprotein; LDL, low-density lipoprotein.
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Table 4 Carotid ultrasonographic ﬁndings in acute coronary syndrome patients without metabolic syndrome.
Complex coronary lesion
Single (n = 120) Multiple (n = 53) P-value
IMTmean (mm) 0.87± 0.17 1.04± 0.21 <0.0001
IMTmin (mm) 0.78± 0.16 0.93± 0.19 <0.0001
IMTmax (mm) 0.96± 0.20 1.15± 0.24 <0.0001
IMTmean > 1.1mm 11 (9%) 25 (47%) <0.0001
IAD (mm) 7.70± 0.96 8.06± 1.01 <0.03
IAD > 8.0mm 37 (31%) 24 (45%) 0.07
LD (mm) 6.14± 0.81 6.22± 0.91 0.55
LD/IAD ratio 1.26± 0.06 1.30± 0.08 0.0002
Carotid remodeling 7 (6%) 18 (34%) <0.0001
Plaque 35 (29%) 26 (49%) <0.02
Calciﬁcation 27 (23%) 18 (34%) 0.11
Values are mean± S.D. or number (%). IAD, interadventitial diameter; IMTmax, maximal intima-media thickness; IMTmean, mean
intima-media thickness; IMTmin, minimal intima-media thickness; LD, luminal diameter.
Table 5 Signiﬁcant independent predictors of multiple complex coronary lesions identiﬁed by logistic regression
analysis.
Chi-square statistica P-value Adjusted OR (95% CI)
Overall patients
Metabolic syndrome 5.74 <0.02 2.06 (1.14—3.73)
Carotid remodeling 21.57 <0.0001 7.44 (3.30—18.25)
Patients without metabolic syndrome
High LDL cholesterolemia 4.68 <0.04 2.45 (1.09—5.61)
Carotid remodeling 11.37 0.0007 6.26 (2.24 —19.33)
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it is likely that the LDL levels were underesti-a Derived from the logistic regression model for multiple, c
lipoprotein; OR, odds ratio.
ary lesions were high levels of LDL cholesterol and
arotid artery remodeling (Table 5).
iscussion
n the present study, we found that high levels
f LDL cholesterol and carotid artery remodeling
ere independent predictors of multiple complex
oronary lesions in male ACS patients without the
etabolic syndrome. The presence of multiple
omplex coronary lesions identiﬁed by coronary
ngiography has been reported to be associated
ith an increased incidence of recurrent ACS [6,7].
oldstein et al. [8] reported that the presence of
ultiple complex plaques was the strongest pre-
ictor of an adverse outcome, especially in those
ith high C-reactive protein levels. Our study sug-
ests that a high LDL cholesterol level and carotid
rtery remodeling might be useful predictors of sec-
ndary cardiovascular events in Japanese men with
CS who do not have the metabolic syndrome.
Our previous study showed that the metabolic
yndrome and carotid artery remodeling were more
m
H
b
sex coronary lesions. CI, conﬁdence interval; LDL, low-density
requently observed in male ACS patients with
ultiple complex coronary lesions. We observed
hat the incidence of abdominal obesity and low
evels of HDL cholesterol, which are characteris-
ics of the metabolic syndrome, were signiﬁcantly
reater in patients with multiple complex coro-
ary lesions. These results support the ﬁndings
f the subanalysis of the MIRACL study and sug-
est that the mechanism responsible for acute
ascular events in patients with the metabolic
yndrome might be related to the underlying
ascular remodeling. However, it is worth not-
ng that the LDL cholesterol level is still a very
mportant risk factor for plaque vulnerability in
CS patients with normal HDL cholesterol levels,
lthough low levels of HDL cholesterol is a strong
redictor of increased cardiovascular disease risk
10—12,24]. Since the LDL cholesterol level was cal-
ulated with the Friedewald formula in this study,ated in patients with the metabolic syndrome.
owever, the etiology of ACS might be different
etween patients with and without the metabolic
yndrome.
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The ﬁndings of our previous and present studies
suggest the usefulness of the LDL to HDL cholesterol
ratio for the secondary prevention of an acute coro-
nary event. There is evidence that the ratio of LDL
to HDL cholesterol is a valuable and standard tool
for evaluating cardiovascular disease risk in all pop-
ulations [25]. However, an optimal cut-off value has
not been clariﬁed. Since our results suggest that the
optimal cut-off value for predicting multiple com-
plex coronary lesions is >3.0, this value might be
useful for the secondary prevention of ACS. Addi-
tional studies are needed to determine the optimal
cut-off ratio of LDL to HDL cholesterol.
We have demonstrated that multiple complex
coronary plaques in patients with ACS are associ-
ated with carotid remodeling, which is deﬁned by
the morphology of common carotid artery, i.e., a
mean value of maximum and minimum carotid IMT
>1.1mm and an interadventitial diameter >8.0mm
[17]. Carotid remodeling remains an important pre-
dictor of coronary plaque vulnerability in patients
without the metabolic syndrome and may be appro-
priate for evaluating systemic vascular remodeling.
It is possible that carotid artery remodeling is
also a useful indicator for assessing the efﬁcacy
of treatments for the secondary prevention of
cardiovascular events in ACS patients. Additional
investigations may provide useful information for
the management of patients with evidence of
carotid artery remodeling.
Study limitations
The lipid proﬁle of the patient might change due to
the hyperadrenergic state early after ST-elevation
in myocardial infarction. These alterations in lipid
and lipoprotein levels generally stabilize by 2
months after an acute event [26]. However, a
recent study showed that the mean serum LDL
cholesterol levels and other lipid variables vary rel-
atively little over the early days after admission for
ACS [27]. Therefore, the lipid levels of the patients
in the present study might not vary widely from
their normal values.
The Justiﬁcation for the Use of Statins in Preven-
tion: an Intervention Trial Evaluating Rosuvastatin
(JUPITER) study group demonstrated that rosuvas-
tatin signiﬁcantly reduced the incidence of major
cardiovascular events in apparently healthy people
without hyperlipidemia but with elevated high-
sensitivity C-reactive protein levels [28]. Goldstein
et al. [8] reported that the presence of multiple
complex plaques was the strongest predictor of
adverse cardiovascular events, especially in those
who had high C-reactive protein levels. We could
not show C-reactive protein and other emerg-M. Kato et al.
ng blood biomarkers proposed to optimize risk
tratiﬁcation of vulnerable patients [29]. However,
-reactive protein was not a reliable marker of
oronary morphologic changes in our study because
t was measured just after the onset of ACS. The
easurement of high-sensitivity C-reactive protein
uring the chronic stage of ACS will be useful for
larifying its relationship with coronary artery mor-
hology.
onclusions
apanese men with ACS who do not have the
etabolic syndrome are more susceptible to
ultiple complex coronary lesions if they have
igh levels of serum LDL cholesterol, which
uggests that they are vulnerable to coronary
laque formation. Furthermore, carotid artery
emodeling is a useful independent predictor of
ultiple complex coronary lesions. High levels
f LDL cholesterol and carotid artery remodel-
ng as well as abdominal obesity and low levels
f HDL cholesterol—–characteristic factors of the
etabolic syndrome—–might be important indi-
ators for assessing the efﬁcacy of aggressive
reatments for the secondary prevention of acute
oronary events.
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